Zydus Lifesciences Limited has informed the Exchange regarding a press release dated July 03, 2023, titled "Zydus receives EIR from the USFDA for its SEZ 1 manufacturing facility at Pharmez, Ahmedabad".
Press Release Jul 03 2023
Filed with NSE · · 1 page · English
Summary by 6ix AI
Zydus Lifesciences Limited has received an Establishment Inspection Report from the USFDA for its manufacturing facility at Pharmez, Ahmedabad, following an inspection conducted in March. The inspection was classified as Voluntary Action Indicated, and the report confirms that the inspection is now closed. This disclosure is made in accordance with regulatory requirements for transparency to investors and the exchange.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Jun 28 2023
- Press Release Jun 19 2023
- Press Release Jun 13 2023
- Press Release Jun 10 2023
- Press Release Jun 09 2023
Later from Zydus Lifesciences
- Press Release Jul 04 2023
- Press Release Jul 07 2023
- Press Release Jul 27 2023
- Press Release Aug 03 2023
- Press Release Aug 11 2023
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences